Zum Hauptinhalt springen

ACL-Inhibition – das Add-on für mehr Kontrolle

Die Inhibition der ATP-Citrat-Lyase (ACL), einem Enzym, das zentral an der Cholesterinsynthese beteiligt ist, stellt einen innovativen Wirkansatz zur Reduktion von LDL-C dar. Wirkstoffe dieser Substanzklasse können als Add-on zu verfügbaren Lipidsenkern LDL-C weiter reduzieren. Damit unterstützt die Therapie mit einem ACL-Inhibitor Patienten dabei, die LDL-Werte zu senken und die Entwicklung der Atherosklerose abzuschwächen1.

Referenzen

  1. Pinkosky SL et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun 2016; 7: 13457.
  2. Mach F et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal 2019; 41: 111-188.
  3. Daiichi Sankyo. Aktuelle NILEMDO Fachinformation.
  4. Daiichi Sankyo. Aktuelle NUSTENDI Fachinformation.
  5. Ray KK et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med 2019; 380: 1022-1032.
  6. Goldberg AC et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA 2019; 322: 1780-1788.
  7. Laufs U et al. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc 2019; 8: e011662.
  8. Ballantyne CM et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis 2018; 277: 195-203.
  9. Ballantyne CM et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol 2020; 27: 593-603.